Skip to content
Agree.net – Lifestyle
Author:
TScan Therapeutics, Inc.
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026